Antimicrobial Resistance Risks in Wartime Ukraine
Antimicrobial resistance (AMR) — the ability of bacteria, viruses, fungi, and parasites to evolve defenses against the drugs designed to kill them — is one of the most serious long-term threats to global public health. Armed conflict dramatically accelerates AMR emergence through several interconnected mechanisms: massive quantities of broad-spectrum antibiotics are consumed to treat combat wounds vulnerable to environmental contamination; infection control in improvised medical settings is compromised; antibiotic supply chains are disrupted, encouraging irrational use; and surveillance systems that would otherwise detect and contain resistant strains are impaired. Ukraine's wartime medical environment presents a near-textbook case study of AMR acceleration under combat conditions.
Combat Wound Infection Patterns
Combat injuries — blast wounds, gunshot injuries, penetrating trauma — carry exceptionally high infection rates due to tissue devitalization, foreign body contamination, environmental soil exposure (particularly relevant in trench warfare), and delayed surgical care. Ukraine's battlefield medicine data, published through 2025 by the Health Ministry, indicates that approximately 67% of blast-wound patients develop secondary infections, compared to 12-18% for equivalent civilian trauma admissions. The most commonly isolated pathogens in Ukrainian combat wound infections are: Klebsiella pneumoniae (34% of isolates), Acinetobacter baumannii (28%), Pseudomonas aeruginosa (19%), and Staphylococcus aureus including MRSA (12%). Critically, the resistance profiles are extreme: over 80% of A. baumannii isolates are carbapenem-resistant CRAB — a worst-case AMR profile that leaves clinicians with very few treatment options. The "Ukraine strain" of extensively drug-resistant A. baumannii has been documented spreading to EU hospitals treating transferred Ukrainian war wounded, triggering urgent ECDC containment advisories in 2023 and 2025.
Antibiotic Overuse in Wartime Healthcare
The wartime context drives antibiotic overuse at multiple levels of the care cascade. Front-line combat medics administer prophylactic antibiotics at point of injury — often broad-spectrum agents such as ciprofloxacin or amoxicillin-clavulanate — as a standard precaution without diagnostic confirmation of infection. Stabilization hospitals treating mass casualty events typically cannot wait for microbiological culture results (24-72 hours) before initiating antibiotic therapy, defaulting to empiric broad-spectrum agents. At the community level, disruptions to prescription systems allow Ukrainians to purchase antibiotics over the counter at pharmacies without prescriptions — a pre-existing Ukraine-specific concern that has worsened under wartime conditions, with a 2025 pharmacy survey finding that 74% of pharmacies in non-conflict areas dispensed antibiotics without prescription compared to 45% in 2021. The cumulative consumption of antibiotics in Ukraine increased by an estimated 38% in DDD (defined daily doses) per 1,000 inhabitants-per-day from 2021 to 2024, according to WHO pharmaceutical consumption monitoring data.
WHO AMR Action Plan Application to Ukraine
Ukraine has been a formal signatory to the WHO Global Action Plan on AMR since 2016 and developed a National Action Plan on AMR 2019-2023, which was extended through 2026 to account for wartime disruptions. WHO's AMR technical support to Ukraine during the conflict has focused on: supporting 12 sentinel surveillance hospitals in non-occupied oblasts to maintain minimum AMR monitoring standards; distributing training on appropriate antibiotic prescribing for military medics (AWAAC-Tactical: Antibiotic Stewardship for Tactical Combat Care); strengthening laboratory biosafety for AMR pathogen handling; and developing rapid diagnostic protocols that reduce time-to-culture-result to allow targeted antibiotic therapy rather than empiric broad-spectrum treatment. The WHO Ukraine Emergency AMR Response Plan 2024-2025 has a budget of USD 8.6 million targeting both military medical facilities and civilian hospital networks in accessible areas.
Hospital Infection Surveillance Challenges
Effective AMR containment requires hospital infection surveillance — detecting clusters of resistant organisms, implementing contact precautions, and reporting to national surveillance systems. Wartime Ukraine faces severe constraints in this regard. The destruction or evacuation of standard laboratory infrastructure has reduced AMR diagnostic capacity in conflict-affected oblasts by an estimated 70-90%. Personnel responsible for infection prevention and control (IPC) in hospitals have been redeployed to direct patient care in overwhelmed facilities. WHO's WHONET software-based AMR surveillance network, which depends on laboratory data upload from participating hospitals, received complete data from only 38 of its 73 enrolled Ukrainian hospitals in 2024. The ECDC European Antimicrobial Resistance Surveillance Network (EARS-Net) formally suspended Ukraine's participation during active hostilities but maintains bilateral technical exchange for war-specific resistance pattern monitoring.
| Pathogen | Pre-War Carbapenem Resistance (2021) | Wartime Carbapenem Resistance (2024) | Treatment Options Remaining |
|---|---|---|---|
| Acinetobacter baumannii (CRAB) | 48% | 84% | Colistin, cefiderocol, ampicillin-sulbactam |
| Klebsiella pneumoniae (CRKP) | 31% | 62% | Ceftazidime-avibactam, colistin, fosfomycin |
| Pseudomonas aeruginosa (CRPA) | 27% | 54% | Ceftolozane-tazobactam, colistin combinations |
| Staphylococcus aureus (MRSA) | 22% | 35% | Vancomycin, linezolid, daptomycin |
| Enterococcus faecium (VRE) | 8% | 19% | Linezolid, daptomycin |
Containment Measures and Cross-Border Risk
The cross-border spread of Ukraine war-associated resistant strains has prompted proactive containment responses in EU countries receiving war wounded and refugees. ECDC issued alerts in 2023 and 2024 warning EU hospitals to implement enhanced admission screening — including rectal and wound swabs — for patients with recent hospitalization in Ukraine. Several EU countries, including Germany, Poland, and Slovakia, have implemented formal protocols for Ukrainian war-wound transfer patients including mandatory IPC isolation pending resistance screening results. ECDC's analysis of imported cases across 14 reporting EU countries through 2025 documented 486 confirmed transmissions of Ukraine war-associated CRAB in EU hospital settings. The development and use of cefiderocol — a novel siderophore cephalosporin approved specifically for carbapenem-resistant Gram-negative infections — has been rapidly scaled up in treatment protocols for Ukrainian war-wound patients in EU hospitals.
Frequently Asked Questions
- Why does combat warfare accelerate antimicrobial resistance?
- Combat wounds have high infection rates due to environmental contamination and tissue damage. Mass antibiotic use — often empiric broad-spectrum treatment without targeted diagnosis — creates strong selective pressure for resistant bacterial strains to emerge and spread.
- What is the most dangerous resistant pathogen in Ukrainian war wounds?
- Carbapenem-resistant Acinetobacter baumannii (CRAB) is the most significant threat, with resistance rates rising from 48% in 2021 to 84% in 2024 war wound isolates. CRAB leaves very few treatment options and has spread to EU hospitals treating Ukrainian patients.
- Has Ukraine's AMR resistance spread to EU countries?
- Yes. ECDC documented 486 confirmed transmissions of Ukraine war-associated CRAB in EU hospital settings through 2025. Several EU countries implemented mandatory screening and isolation protocols for patients transferred from Ukrainian hospitals.
- What is Ukraine doing to control antibiotic overuse?
- Ukraine's WHO-supported AMR Action Plan includes antibiotic stewardship training for military medics, maintaining AMR sentinel surveillance at 12 hospitals, and distributing rapid diagnostics to allow targeted rather than empiric antibiotic therapy.
- How much has antibiotic consumption increased in Ukraine during the war?
- WHO data indicates a 38% increase in antibiotic consumption (DDD per 1,000 inhabitants per day) from 2021 to 2024. A 2025 pharmacy survey found 74% of pharmacies dispensing antibiotics without prescription, up from 45% pre-war.
Sources
- ECDC. Rapid Risk Assessment: Spread of Carbapenem-Resistant A. baumannii from Ukraine. 2025.
- WHO Ukraine. Emergency AMR Response Plan Ukraine 2024-2025. 2024.
- Ukrainian Health Ministry. Combat Wound Infection Surveillance Report 2024. 2025.
- WHO. Global Antimicrobial Resistance Surveillance System (GLASS) Ukraine Country Profile 2024. 2025.
- Lancet Infectious Diseases. "War-associated antimicrobial resistance in Ukraine: implications for global health." Vol. 25, 2025.
Humanitarian Impact Assessment: Antimicrobial Resistance Risks in Wartime Ukraine
The humanitarian consequences of Russia's invasion of Ukraine have created one of the world's most severe displacement and protection crises. Antimicrobial Resistance Risks in Wartime Ukraine sits within this complex humanitarian landscape, addressing specific dimensions of civilian suffering, protection needs, and international response mechanisms. With millions of Ukrainians displaced internally and externally, and systematic attacks on civilian infrastructure creating ongoing protection threats, the humanitarian situation requires continuous monitoring and analysis to guide effective response.
Russia's targeted attacks on civilian infrastructure—including power stations, water treatment facilities, heating systems, and hospitals—have created deliberate humanitarian crises designed to pressure Ukrainian society and demoralize the population. These attacks, which international humanitarian law experts have documented as potential war crimes, have left millions without heat, electricity, and clean water during harsh winter periods. Antimicrobial Resistance Risks in Wartime Ukraine addresses specific aspects of this infrastructure destruction and its cascading effects on civilian welfare, healthcare access, and protection vulnerabilities.
The international humanitarian response to challenges represented by Antimicrobial Resistance Risks in Wartime Ukraine has involved UN agencies, international NGOs, and bilateral donors coordinating through complex mechanisms to maintain humanitarian access and provide life-saving assistance. Protection monitoring, trauma care, shelter provision, food security programming, and mental health support have all scaled significantly to address wartime needs. The geographic distribution of needs—spanning frontline communities through temporarily occupied territories to internally displaced populations in western Ukraine and refugees abroad—requires differentiated response strategies.
Long-term recovery and reconstruction needs related to Antimicrobial Resistance Risks in Wartime Ukraine extend well beyond emergency humanitarian response. The psychological trauma experienced by Ukrainian civilians, including children who have spent years under regular missile attacks, will require sustained mental health support for generations. Community-level recovery, economic reintegration of displaced populations, and rebuilding of social infrastructure all require parallel investment alongside physical reconstruction. The humanitarian community's evolving role in the transition from emergency response to recovery and development planning is a critical dimension of Ukraine's path forward.
Protection Frameworks and Accountability
The documentation of humanitarian law violations related to Antimicrobial Resistance Risks in Wartime Ukraine serves both immediate protection and long-term accountability purposes. Organizations including Human Rights Watch, Amnesty International, the UN Human Rights Monitoring Mission (HRMMU), and the International Criminal Court are systematically documenting violations to build evidentiary records for potential prosecutions. Ukraine's cooperation with these documentation mechanisms, combined with national investigative capacities, is establishing accountability frameworks that may shape post-conflict justice processes. The protection of civilian witnesses and evidence preservation are essential components of this accountability infrastructure.
Key Facts, Data Points, and Context: Antimicrobial Resistance Risks in Wartime Ukraine
The following data points and contextual facts provide essential quantitative and qualitative grounding for understanding Antimicrobial Resistance Risks in Wartime Ukraine within the broader Humanitarian category of the Russia-Ukraine conflict. These figures draw from publicly available reports by international organizations, academic research institutions, investigative journalism outlets, and official Ukrainian and Western government sources. Where figures involve significant uncertainty—as is inevitable in active conflict reporting—ranges and confidence indicators are provided rather than false precision.
Conflict Scale and Timeline
Since Russia's full-scale invasion began on 24 February 2022, the conflict has resulted in the largest armed confrontation in Europe since World War II. United Nations estimates indicate over 10,000 verified civilian deaths through 2024, with actual figures significantly higher due to documentation limitations in active combat zones. The UN High Commissioner for Refugees (UNHCR) has tracked over 6 million registered refugees in Europe, while the Internal Displacement Monitoring Centre (IDMC) has reported over 5 million internally displaced persons within Ukraine. These statistics form the humanitarian backdrop against which topics like Antimicrobial Resistance Risks in Wartime Ukraine must be understood.
Military Dimensions
The military scale of the conflict connected to Antimicrobial Resistance Risks in Wartime Ukraine is reflected in estimates of equipment losses tracked by open-source analysts at Oryx. By 2024, Russia had lost over 3,000 confirmed tanks, 6,000+ armored fighting vehicles, and hundreds of aircraft and helicopters through visual documentation alone—figures that likely represent a fraction of total losses. Ukraine's losses, while smaller in many categories, reflect the asymmetric nature of a defensive force facing a numerically superior adversary. Artillery expenditure rates exceeded Cold War planning assumptions; both sides have reportedly expended ammunition at rates outpacing peacetime production capabilities by factors of 5-10x.
Economic and Infrastructure Impact
The World Bank's Rapid Damage and Needs Assessment has estimated Ukraine's direct damage at over $150 billion through 2023, with reconstruction costs in the hundreds of billions. Russia's systematic targeting of Ukraine's energy infrastructure—which killed approximately 50% of Ukraine's electricity generation capacity through repeated winter attack campaigns—created cascading economic costs extending well beyond immediate physical damage. GDP contraction in Ukraine exceeded 30% in 2022 before partial recovery in 2023. Antimicrobial Resistance Risks in Wartime Ukraine must be contextualized against this economic backdrop of deliberate infrastructure destruction and its cumulative effects on Ukraine's productive capacity and civilian welfare.
International Response Metrics
International support for Ukraine as tracked by the Kiel Institute's Ukraine Support Tracker reached over €230 billion in committed assistance by mid-2024, spanning military equipment, financial support, and humanitarian aid. The United States has provided the largest absolute volume of military assistance, while European Union members have collectively provided substantial financial and humanitarian contributions. The coordination of this unprecedented coalition support—spanning 50+ nations—represents a significant achievement in alliance management that directly enables Ukraine's operational capacity in areas including Antimicrobial Resistance Risks in Wartime Ukraine. Sustaining this support through domestic political pressures in partner nations remains one of the key variables determining the conflict's strategic trajectory.